A megamerger of this sort would vault Shell’s market cap closer to ExxonMobil’s $468 billion and likely beyond Chevron’s $248 billion.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.
The choppy waters predicted for the cruise industry this year were based on the very real risks of trade wars and real wars.
Novo and Hims’ April team-up turned the two firms from competitors into collaborators at just the right moment.
A record number of drones are on display at the world’s largest aerospace event in Paris this week, marking a major industry milestone.
With no immediate end in sight, analysts are weighing multiple possibilities that could affect prices down the line.
The US and New Zealand are the only two countries that allow pharmaceutical companies to directly advertise to patients on TV.
The deal is the Trump administration’s attempt to stake out a new path for balancing national security and the influx of foreign capital.
For key US eVTOL players Joby Aviation and Archer Aviation, the Paris Air Show comes at a critical moment.
NASA is looking to decrease its dependency on key contractor SpaceX, but Jeff Bezos’s Blue Origin is going nowhere at exactly the wrong time.
Elon Musk is again sleeping at Tesla’s offices again, but that may not be enough to restart the top US EV-maker’s engine.
The Switch 2 sold 3.5 million units in its first four days, and Nintendo’s targeting 15 million units for this fiscal year.
In an interview with the Financial Times, Starbucks CEO Brian Niccol said the company is exploring a partial sale of its China business.
Could GLP-1 weight loss drugs like Ozempic and changing economic winds really take a bite out of the almighty Big Mac?
Like the rest of its pre-streaming Hollywood peers, Warner Bros. Discovery finds itself trapped between two eras.
Scale for scale’s sake appears to have become passé, with conglomerates jockeying for market share with a more focused brand identity.